Results 51 to 60 of about 65,986 (255)

Development and Validation of a Prognostic Classifier Based on Lipid Metabolism-Related Genes for Breast Cancer [Corrigendum]

Journal of Inflammation Research, 2022
Wang N, Gu Y, Li L, et al. J Inflamm Res. 2022;15:3477–3499. The authors have advised due to an error that occurred inadvertently at the time of figure assembly, the scratch test result of si-SDC1 MBA-MD-231 cells were wrongly placed in the ...
Wang N, Gu Y, Li L, Chi J, Liu X, Xiong Y, Zhong C   +6 more
doaj  

Population testing for cancer predisposing BRCA1/BRCA2 mutations [PDF]

, 2014
Background: Technological advances raise the possibility of systematic population-based genetic testing for cancer-predisposing mutations, but it is uncertain whether benefits outweigh disadvantages.
Wardle, J
core  

Genetic Ablation and Multi‐Omics Profiling Reveal CEP55 as a Key Driver of Tumorigenesis in Diverse Cancer Models

Advanced Science, EarlyView.
Genetic ablation of Cep55 in Pten‐deficient mouse models delays tumorigenesis. Integrated multi‐omics analyses (proteomics, phosphoproteomics, and spatial transcriptomics) reveal that CEP55 regulates oncogenic signaling (RAS/ERK, PI3K/AKT), integrin/FAK‐mediated adhesion, extracellular matrix (ECM) remodeling, and endocytosis.
Behnam Rashidieh, Yuanhao Yang, Amanda Louise Bain, Phillip Theron, Catharina Vosloo, Sahar Keshvari, Parinaz Ahangar, Brydie Bowden, Simon M. Tria, Ben B. Wang, Sandra Isenmann, Nicholas J. Westra van Holthe, Zherui Xiong, Hani Vu, Sowmya Sharma, Asmerom Sengal, J. Alejandro Lopez, John Finnie, Antonella Papa, Pascal H.G. Duijf, Quan Nguyen, Pirjo M. Apaja, Kum Kum Khanna   +22 more
wiley   +1 more source

Is it possible to improve primary therapy of advanced ovarian cancer?

Медицинский совет, 2020
In 2011, a standard approach to the treatment of primary ovarian cancer (OC) included a cytoreductive surgery, which could be performed after 2–3 cycles of neoadjuvant chemotherapy, and chemotherapy consisting of platinum and taxanes.
S. V. Khokhlova
doaj   +1 more source

EDNRA Forms a Positive Feedback Loop with the Hippo/YAP Axis to Drive Triple‐Negative Breast Cancer Progression

Advanced Science, EarlyView.
Endothelin receptor type A (EDNRA) and the Hippo/YAP pathway form a self‐reinforcing loop that sustains triple‐negative breast cancer. EDNRA activates YAP through Gαq/11–Rho/ROCK–LATS signaling, while YAP/TEAD4 reciprocally drives EDNRA transcription.
Zehao Hong, Boyang Li, Jiahui Xu, Ruonan Lin, Jinghao Pan, Chenlu Fang, Boxiang Zhang, Lucy Yue Lau, Richard J. Aldridge, Elizabeth A. Whitmore, Yi Chen   +10 more
wiley   +1 more source

BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects

Cancer Management and Research, 2020
Winston Wong,1 Alexander G Raufi,1,2 Rachael A Safyan,1 Susan E Bates,1,3 Gulam A Manji1,4 1Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital Herbert Irving Pavilion, New York, NY 10032, USA ...
Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA   +4 more
doaj  

The latest first-line treatment options for ovarian cancer: focus on maintenance therapy

Медицинский совет, 2020
Ovarian cancer is one of the leading causes of death from gynecologic cancers in Russia: in 2018, 7616 women died from this disease and the proportion of patients who is under observation for 5 years or more was only 3.4%, which probably indicates very ...
A. A. Rumyantsev
doaj   +1 more source

Nanoparticle‐Mediated TIPE1 mRNA Delivery Enhances Paclitaxel Sensitivity in Triple‐Negative Breast Cancer by Modulating RAB7A Ubiquitination‐Associated Stability and Autophagy

Advanced Science, EarlyView.
TIPE1m NPs nanoparticles restore TIPE1 expression, promote RAB7A ubiquitination and degradation, suppress autophagic flux, and resensitize paclitaxel‐resistant triple‐negative breast cancer to therapy. ABSTRACT Acquired paclitaxel (PTX) resistance remains a major obstacle in triple‐negative breast cancer (TNBC) treatment.
Wei Hu, Qishuai Chen, Yan Ma, Yang Liu, Xianing Dong, Wenjuan Wei, Jianxin Du, Shusheng Qiu, Maojin Tian, Peiqing Zhao   +9 more
wiley   +1 more source

Outcome of BRCA 1/2-mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V).

, 2014
135 Background: Veliparib (V) (ABT-888) is an oral, potent inhibitor of PARP 1/2. PARP inhibitors have preclinical and clinical efficacy in BRCA+ malignancies. There are genotypic and phenotypic similarities between BRCA+ cancers, serous ovarian cancer
Brian Kiesel, Jan Hendrik Beumer, Edward Chu, Stacie Peacock Shepherd, Robert Morgan, Chandra Prakash Belani, Ronald G. Stoller, Helen K. Chew, Vincent L. Giranda, Shannon Puhalla, Antoinette R. Tan, Shalu Pahuja, Agustin A. Garcia, Jing Yu, Alice P. Chen, Yan Lin, Leonard Joseph Appleman, Hussein Abdul-Hassan Tawbi, James J. Lee   +18 more
core   +1 more source

BRCA Mutations and Fertility Preservation.

, 2023
Hereditary cancers mostly affect the adolescent and young adult population (AYA) at reproductive age. Mutations in BReast CAncer (BRCA) genes are responsible for the majority of cases of hereditary breast and ovarian cancer.
Isabelle Demeestere, Joana Dias Nunes, Dias Nunes, Joana, Melody Devos, Devos, Melody, Demeestere, Isabelle   +5 more
core   +1 more source